Imaging and evaluation of corneal vascularization using fluorescein and indocyanine green angiography

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 2, 2012, Pages 650-658

  Anijeet, Deepa R ^a,b   Zheng, Yalin ^a   Tey, Adrian ^b   Hodson, Martin ^b   Sueke, Henri ^a,b   Kaye, Stephen B ^a,b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD VESSEL DIAMETER; CLINICAL ARTICLE; CORNEA NEOVASCULARIZATION; CORNEA STROMA; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; IMAGE ANALYSIS; INDOCYANINE GREEN ANGIOGRAPHY; MALE; PHOTOGRAPHY; PRIORITY JOURNAL; SCAR FORMATION; EVALUATION; METHODOLOGY; MIDDLE AGED; RETINA MACULA DEGENERATION;

COLORING AGENT; CONTRAST MEDIUM; DIAGNOSTIC AGENT; FLUORESCEIN; INDOCYANINE GREEN;

ADULT; AGED; COLORING AGENTS; CONTRAST MEDIA; CORNEAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN; FLUORESCEIN ANGIOGRAPHY; HUMANS; INDOCYANINE GREEN; MACULAR DEGENERATION; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84859260749     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.11-8014     Document Type: Article

References (23)

1. Cursiefen C, Chen L, Saint-Geniez M, et al. Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci U S A. 2006;103:11405-11410.
2. Cursiefen C, Rummelt C, Junemann A, et al. Absence of blood and lymphatic vessels in the developing human cornea. Cornea. 2006; 25:722-726.
3. Bock F, Onderka J, Dietrich T, et al. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci. 2007;48:2545-2552.
4. Chang JH, Gabison EE, Kato T, Azar DT. Corneal neovascularization. Curr Opin Ophthalmol. 2001;12:242-249.
5. Samolov B, Steen B, Seregard S, van der Ploeg I, Montan P, Kvanta A. Delayed inflammation-associated corneal neovascularization in MMP-2-deficient mice. Exp Eye Res. 2005;80:159-166.
6. Lee P, Wang CC, Adamis AP. Ocular neovascularization: an epidemiologic review. Surv Ophthalmol. 1998;43:245-269.
7. Dana MR, Streilein JW. Loss and restoration of immune privilege in eyes with corneal neovascularization. Invest Ophthalmol Vis Sci. 1996;37:2485-2494.
8. Maguire MG, Stark WJ, Gottsch JD, et al. Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies: Collaborative Corneal Transplantation Studies Research Group. Ophthalmology. 1994;101:1536-1547.
9. Williams KA, Roder D, Esterman A, et al. Factors predictive of corneal graft survival: report from the Australian Corneal Graft Registry. Ophthalmology. 1992;99:403-414.
10. Lin CT, Hu FR, Kuo KT, et al. The different effects of early and late bevacizumab (Avastin) injection on inhibiting corneal neovascularization and conjunctivalization in rabbit limbal insufficiency. Invest Ophthalmol Vis Sci. 2010;51:6277-6285.
11. Habot-Wilner Z, Barequet IS, Ivanir Y, Moisseiev J, Rosner M. The inhibitory effect of different concentrations of topical bevacizumab on corneal neovascularization. Acta Ophthalmol. 2010;88: 862-867.
12. Pérez-Santonja JJ, Campos-Mollo E, Lledó-Riquelme M, Javaloy J, Alió JL. Inhibition of corneal neovascularization by topical bevacizumab (anti-VEGF) and sunitinib (anti-VEGF and anti-PDGF) in an animal model. Am J Ophthalmol. 2010;150:519-528.
13. Dastjerdi MH, Al-Arfaj KM, Nallasamy N, et al. Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. Arch Ophthalmol. 2009;127:381-389.
14. Sharma A, Bettis DI, Cowden JW, Mohan RR. Localization of angiotensin converting enzyme in rabbit cornea and its role in controlling corneal angiogenesis in vivo. Mol Vis. 2010;23:720-728.
15. Koenig Y, Bock F, Horn F, Kruse F, Straub K, Cursiefen C. Shortand long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2009;247:1375-1382.
16. Easty DL, Bron AJ. Fluorescein angiography of the anterior segment: its value in corneal disease. Br J Ophthalmol. 1971;55: 671-682.
17. Landsman ML, Kwant G, Mook GA, Zijlstra WG. Light-absorbing properties, stability, and spectral stabilization of indocyanine green. J Appl Physiol. 1976;40:575-583.
18. Fossarello M, Peiretti E, Zucca I, Serra A. Photodynamic therapy of corneal neovascularization with verteporfin. Cornea. 2003;22: 485-488.
19. Zheng Y, Gandhi JS, Stangos AN, Campa C, Broadbent DM, Harding SP. Automated segmentation of foveal avascular zone in fundus fluorescein angiography. Invest Ophthalmol Vis Sci. 2010;51: 3653-3659.
20. Li Q, Sone S, Doi K. Selective enhancement filters for nodules, vessels, and airway walls in two- and three-dimensional CT scans. Med Phys. 2003;30:2040-2051.
21. Martinez-Perez ME, Highes AD, Stanton AV, et al. Retinal vascular tree morphology: a semi-automatic quantification. IEEE Trans Biomed Eng. 2002;49:912-917.
22. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-174.
23. Cursiefen C, Kuchle M, Naumann GO. Angiogenesis in corneal diseases: histopathologic evaluation of 254 human corneal buttons with neovascularization. Cornea. 1998;17:611-613.